REGULATORY

Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index

July 24, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council’s (Chuikyo) expert subcommittee on cost-effective assessments approved a plan to create guidelines that provide a standard method for analyzing cost-effectiveness at a meeting on July 22. The method will utilize QALY (quality-adjusted life years)…

To read the full story

FY2016 Drug Pricing Reform
August 18, 2015
Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015

REGULATORY

Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…